Nilsine Partners’s AstraZeneca AZN Stock Holding History

Nilsine Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$496K	Buy	2,617 +34	+1%	+$6.39K	0.03%	304
2026 Q1	$484K	Sell	2,583 -506	-16%	-$97.6K	0.04%	289
2025 Q4	$568K	Sell	3,089 -1,248	-29%	-$219K	0.05%	259
2025 Q3	$665K	Sell	4,337 -15	-0.3%	-$2.27K	0.06%	249
2025 Q2	$608K	Buy	4,352 +4	+0.1%	+$561	0.06%	240
2025 Q1	$639K	Sell	4,348 -171	-4%	-$24.7K	0.07%	217
2024 Q4	$592K	Sell	4,519 -36	-0.8%	-$5.04K	0.06%	228
2024 Q3	$710K	Sell	4,555 -70	-2%	-$11.3K	0.09%	201
2024 Q2	$721K	Buy	4,625 +857	+23%	+$129K	0.1%	200
2024 Q1	$510K	Hold	3,768	–	–	0.07%	227
2023 Q4	$507K	Sell	3,768 -521	-12%	-$67.7K	0.08%	223
2023 Q3	$581K	Sell	4,289 -17	-0.4%	-$2.32K	0.09%	208
2023 Q2	$616K	Sell	4,306 -42	-1%	-$6.18K	0.09%	209
2023 Q1	$604K	Buy	+4,348	New	+$585K	0.09%	205

Other funds holding AZN

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

Nilsine Partners's AZN Position: Q2 2026 in Review

Nilsine Partners increased its AstraZeneca (AZN) stake by 1.3% in Q2 2026, buying an estimated $6.39K and bringing the position to 2,617 shares worth $496K. The position accounts for 0.03% of the portfolio, ranked #304.

Nilsine Partners first reported a position in AZN in Q1 2023 and has held it in 14 quarters since. The position peaked at $721K in Q2 2024. 443 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Nilsine Partners held 2,617 shares of AstraZeneca worth $496K as of Q2 2026.
Nilsine Partners bought 34 AstraZeneca shares in Q2 2026, an estimated $6.39K.
AstraZeneca made up 0.03% of Nilsine Partners's portfolio in Q2 2026, its #304 holding.
Nilsine Partners first reported a position in AstraZeneca in Q1 2023 and has held it in 14 quarters since.
Nilsine Partners's AstraZeneca position peaked at $721K in Q2 2024.
443 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Nilsine Partners's 13F filing for Q2 2026, filed 24 Jul 2026.